CHICAGO–(Organization WIRE)–Aug 30, 2022–
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”), a targeted remedy, immuno-oncology business targeted on establishing opportunity to start with-in-class oncology prescription drugs, currently declared that it has been chosen to perform an oral presentation masking the novel THIO platform at the XIV International Spherical Desk on Nucleosides, Nucleotides, and Nucleic Acids, which will be taking position in Stockholm, Sweden on August 28 – 31, 2022.
This scientific trade presentation will summarize an surprising, however promising, home of MAIA’s THIO platform, a modified nucleoside – 6-thio-2’-deoxyguanosine (6-thio-dG), as a opportunity anticancer agent. It will reveal the importance of cancer mobile telomeric DNA structural and purposeful integrity, as properly as therapeutically appealing option to induce strain, enhance innate sensing and adaptive antitumor immunity by way of “cancer mobile self-produced” chemical modification of telomeres.
“Since their discovery, telomeres and telomerase of most cancers cells have drawn major scientific interest as appealing targets as probably selective anti-tumor therapies. We are thrilled to have been specified the opportunity to present our conclusions with regards to the novel THIO platform as a modified nucleoside, telomerase substrate precursor, and likely anticancer agent,” claimed Sergei Gryaznov, Ph.D., Main Scientific Officer of MAIA. “We have shown that the compound is a perhaps powerful and particular anticancer agent that also activates each innate and adoptive immune units through induction of cGAS/STING pathway. Intriguingly, administration of THIO has proven the opportunity to conquer resistance to immune checkpoint blockade, by anti-PD-1 or anti-PD-L1 agents, in highly developed in vivo syngeneic cancer versions, top to profound anticancer results, and to induction of tumor form unique extended-expression anticancer memory in mice.”
“We are delighted to have been chosen to present our information at the XIV International Round Table,” claimed Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “This reflects the scientific community’s desire in our distinctive technique to remedy of cancer.”
Presentation Title: “Telomerase-Driven Telomeric DNA Modification in Cancer Cells Potential customers to Economical Induction of cGAS-mediated Innate and Adoptive Immune Responses”
Lead Authors: Sergei M. Gryaznov, MAIA Biotechnology, Inc., Chicago, IL and Jerry W. Shay, University of Texas, Southwestern Health care Heart, Dallas, TX
Dates: Sunday, August 28, 2022 to Wednesday, August 31, 2022
Area: Karolinska Institutet Campus Solna, in the building Aula Medica. Nobels väg 6, Solna
For much more data about the oral presentation, make sure you go to www.maiabiotech.com/publications/.
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-focusing on agent currently in clinical growth to assess its activity in non-little mobile lung cancer (NSCLC), in sequential administration with cemiplimab, a PD-1 inhibitor made by Regeneron. Telomeres participate in a elementary job in the survival of cancer cells and their resistance to existing therapies. THIO is staying developed as a next or later line of treatment for NSCLC for clients that have progressed past the standard-of-care routine of current checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a qualified therapy, immuno-oncology corporation focused on the improvement and commercialization of potential initial-in-course medication with novel mechanisms of motion that are supposed to meaningfully improve and increase the lives of individuals with cancer. Our direct system is THIO, a probable to start with-in-class most cancers telomere focusing on agent in medical improvement for the procedure of NSCLC people with telomerase-positive most cancers cells. For much more details, please take a look at www.maiabiotech.com.
Forward Wanting Statements
MAIA cautions that all statements, other than statements of historic points, contained in this press release, are ahead-searching statements. Forward-wanting statements are subject to recognized and unknown threats, uncertainties, and other things that could cause our or our industry’s precise outcomes, levels or activity, general performance or achievements to be materially distinctive from individuals expected by these types of statements. The use of words these types of as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other equivalent expressions are intended to recognize forward wanting statements. However, the absence of these phrases does not signify that statements are not forward-looking. For instance, all statements we make regarding (i) the initiation, timing, expense, development and effects of our preclinical and clinical experiments and our research and development courses, (ii) our skill to progress products candidates into, and efficiently complete, scientific research, (iii) the timing or probability of regulatory filings and approvals, (iv) our ability to create, manufacture and commercialize our product candidates and to enhance the manufacturing method, (v) the amount and diploma of industry acceptance of our product or service candidates, (vi) the size and advancement probable of the markets for our solution candidates and our potential to provide people markets, and (vii) our expectations pertaining to our capacity to get hold of and maintain mental home security for our merchandise candidates, are forward looking. All ahead-on the lookout statements are based on recent estimates, assumptions and expectations by our management that, although we consider to be acceptable, are inherently unsure. Any forward-seeking statement expressing an expectation or perception as to future gatherings is expressed in good religion and considered to be realistic at the time this kind of forward-wanting statement is made. On the other hand, these statements are not guarantees of potential functions and are subject matter to pitfalls and uncertainties and other aspects over and above our command that may perhaps bring about real benefits to vary materially from individuals expressed in any ahead-seeking statement. Any forward-searching statement speaks only as of the day on which it was designed. We undertake no obligation to publicly update or revise any forward-hunting statement, no matter whether as a end result of new info, long run activities or or else, other than as expected by regulation. In this launch, unless the context involves usually, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
See resource edition on businesswire.com:https://www.businesswire.com/information/household/20220830005383/en/
Speak to: ICR Westwicke
Search term: ILLINOIS EUROPE SWEDEN UNITED STATES NORTH The us
Marketplace Search term: ONCOLOGY Well being Scientific TRIALS Research SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
Source: MAIA Biotechnology, Inc.
Copyright Company Wire 2022.
PUB: 08/30/2022 11:07 AM/DISC: 08/30/2022 11:07 AM